OTCMKTS:SSMXY - Sysmex Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$32.64
▲ +0.83 (2.61%)

This chart shows the closing price for SSMXY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sysmex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SSMXY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SSMXY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Sysmex in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $32.64.

This chart shows the closing price for SSMXY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Sysmex. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/30/2022CitigroupUpgradeNeutral ➝ Buy
11/26/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral
7/29/2021Jefferies Financial GroupDowngradeBuy ➝ Hold
6/28/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform
2/12/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral
11/25/2020Smith Barney CitigroupUpgradeSell ➝ Neutral
6/5/2020Daiwa Capital MarketsUpgradeNeutral ➝ Outperform
4/16/2020CitigroupDowngradeNeutral ➝ Sell
11/26/2019MizuhoDowngradeBuy ➝ Neutral
(Data available from 8/12/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/14/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/15/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sysmex logo
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
Read More

Today's Range

Now: $32.64
Low: $32.43
High: $32.68

50 Day Range

MA: $31.69
Low: $28.33
High: $35.83

52 Week Range

Now: $32.64
Low: $27.54
High: $69.41

Volume

19,688 shs

Average Volume

57,815 shs

Market Capitalization

$13.68 billion

P/E Ratio

34.72

Dividend Yield

1.32%

Beta

0.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Sysmex?

The following Wall Street research analysts have issued research reports on Sysmex in the last year: Citigroup Inc., and Daiwa Capital Markets.
View the latest analyst ratings for SSMXY.

What is the current price target for Sysmex?

0 Wall Street analysts have set twelve-month price targets for Sysmex in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sysmex in the next year.
View the latest price targets for SSMXY.

What is the current consensus analyst rating for Sysmex?

Sysmex currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SSMXY will outperform the market and that investors should add to their positions of Sysmex.
View the latest ratings for SSMXY.

What other companies compete with Sysmex?

How do I contact Sysmex's investor relations team?

Sysmex's physical mailing address is 1-5-1 Wakinohama-Kaigandori Chuo-ku, Kobe M0, 651-0073. The company's listed phone number is (178) 265-0500. The official website for Sysmex is www.sysmex.co.jp. Learn More about contacing Sysmex investor relations.